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ABSTRACT 
Objectives: A retrospective study was conducted to evaluate 
the antibody response of Cuban patients infected with human 
immunodeficiency virus (HIV-1 against two consensus pep- 
tides from the third variable domain (V3) loop of glycoprotein 
gpl20. 
Methods: The study included sera from IO individuals at dif- 
ferent stages of disease. Two 15meric synthetic peptides 
designed from a consensus sequence, belonging to group B 
or C of HIV-I, were used to determine antibody titers and avid- 
ity indexes in an indirect enzyme-linked immunoassay. 
Results: A high reactivity against both peptides was detected, 
with 80% of the sera reacting with at least one of the pep- 
tides. The antibody titers and avidity indexes did not correlate 
with disease progression. Additionally, for one of the patients 
from whom the virus had been isolated, a higher avidity index 
was found against the homologous peptide. 
Conclusions: This study showed high reactivity against two 
consensus peptides from the V3 loop of gpl20 among patients 
with HIV. Large scale studies are needed to determine whether 
the titers or avidity of anti-V3 antibodies, at the early stages of 
infection, are predictive of disease progression. Both peptides 
are candidates for inclusion in experimental vaccines. 
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The rapid sequence evolution of the human immuno- 
deficiency virus (HIV) genome is one of the mo’st impor- 
tant obstacles to the development of an effective vaccine. 
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The external envelope glycoprotein (gp 120) which plays 
a central role in the mechanisms of viral entry into tar- 
get cells, is the most polymorphic of the HIV-1 antigens.’ 
The principal neutralizing determinant of HIV-1 has been 
located in the third variable region (v3) loop of gp120.2 
This domain is involved in post binding events that lead 
to the fusion between virus and cell membranes, possi- 
bly interacting with a second receptor at the cell surface. 
Although the V3 loop is a polymorphic region, some 
restriction in its variability has been identified, mainly at 
the central tetrapeptide.1,3 
Synthetic peptides have been extensively used in the 
study of immune response against V3 in individuals 
infected with HIV-l and vaccine recipients,* and V3 pep- 
tide enzyme-linked immunoassay (ELBA) has been pro- 
posed as a method to characterize the subtype of the 
circulating viru~.~-~~ This article describes the results of 
a retrospective study of the evaluation of the antibody 
response (titers and avidity index [AI]) in 10 Cuban 
patients infected with HIV-l against two consensus pep- 
tides from the V3 loop. The correlation between the sero- 
logic response against both peptides and disease 
progression was examined. For one of the patients, the 
V3 ELISA reactivity could be associated with the genotype 
of the infecting viral isolate. 
MATERIAL AND METHODS 
Patients and Sera 
A panel of 45 serum samples from 10 Cuban patients 
infected with HIV-l was evaluated. Several samples from 
each patient, collected over a 3-year period were stored 
at the Institute of Tropical Medicine Pedro Kouri and San- 
tiago de la Vegas Sanatorium, Havana City, Cuba. In 5 of 
the 10 patients the infecting virus came directly or indi- 
rectly from Africa, but in the others the origin of the infec- 
tion was unknown. Criteria from the Centers for Disease 
Control and Prevention (CDC) were used to classify the 
clinical stage of each patient; these criteria were used to 
categorize all patients: acquired immunodeficiency syn- 
drome (AIDS) or non-AIDS; progressor or nonprogressor. 
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Synthetic Peptides 
Peptides were obtained from the Center for Genetic Engi- 
neering and Biotechnology, Cuba. Peptides were synthe- 
sized using the solid-phase method.‘l Two peptides were 
used in this study: ~4-6 (KSIHIGPGRAFYATG) and C4-7 
(KSIRIGPGQAFYATG), which represent respectively the 
consensus of groups 1 and 2, according to the pheno- 
typic V3 classification proposed by Myers et a1.l 
Enzymatic Immunoassays 
Microtiter plates (MaxiSorp F8, Nalge Nunc International 
Corporation, Rochester, NY) were coated at 5 kg/rnL of 
peptides in 100 p,L per well of diluted peptides in 50 mM 
Na,CO,/NaHCO,, pH 9.7 for 3 hours at 37°C. After three 
washes with phosphate buffered saline (PBS) containing 
0.05% of Tween 20; 100 PL of the blocking solution (0.5% 
bovine serum albumin @A) in PBS + 0.05% Tween 20) 
was dispensed and incubated for 1 hour at 37°C. Dilu- 
tions of human sera were made in a buffered solution 
containing 0.5% BSA, 0.5% Tween 20, and 5% calf serum 
in PBS. Sera were first diluted 1:50; then serial doubling 
dilutions were made. Portions of diluted sera (100 pL) 
were added to wells; then the plates were incubated for 
1 hour at 37°C. Plates were again washed three times and 
horseradish peroxidase (HRP)-linked antihuman 
immunoglobulin (IgG) (Amersham, Little Chalfont, Eng- 
land) diluted 1:30,000 (in the same dilution buffer) was 
dispensed at 100 PL per well for 1 hour at room tem- 
perature; then plates were washed as before. Positive reac- 
tions were visualized with o-phenylene diamine (OPD) 
and H,O, in 0.1 M of citric acid, 0.2 M NaH,PO*, pH 5; the 
reaction was stopped with 100 FL of 12.5% H,SO,. Mea- 
surements of optical densities (OD) at 492 nm were made 
in a MicroELISA reader (Titertek Multiskan Plus@, 
Huntsville, AL). 
Samples showing absorbance values three times 
above the standard deviations of negative control serum 
were recorded as positive. Antibody titers were defined 
as the highest dilution of the sera giving an OD value 
above the cutoff. 
To estimate the AI for each serum-peptide combina- 
tion, an intermediate step of incubation with ammonium 
thiocyanate was implemented as reported by others.12 
The results were plotted in a logarithmic graph, and 
adjusted using a third degree polynomial equation. The 
OD value for the sample without thiocyanate incubation 
is referred to as the maximal OD for that serum. The con- 
centration of ammonium thiocyanate that caused a 50% 
reduction in the maximal OD was considered as the AI 
of this serum. An increase of more than 27% (double the 
interassay variation coefficient) of the AI between the 
first and the last serum sample from the same patient 
was defined as avidity maturation of the antibody 
response against the corresponding peptide.13 
Statistical Analysis 
Chi-square for 2 X 2 contingency tables, Fisher’s exact 
probability withyates correction, and Student’s t-test were 
applied to compare the reactivity against both peptides 
and the clinical classification groups. The antibody titers 
were logarithmically transformed for these analyses. The 
computer package Statistica (StatSoft Inc., Tulsa, OK) was 
used. 
RESULTS 
Reactivity of HIV-l-Positive Sera 
against ~3 Consensus Peptides 
Of all serum samples analyzed against the V3 peptides, 
55% of the sera (25/45) were reactive against both pep- 
tides in ELISA, 28.9% (13/45) of the samples reacted 
against only one of the two peptides, and 15.6% (7/45) 
were non-reactive. No significant difference in the reac- 
tivity against peptides C4-6 (77.7%) and C4-7 (62.2%) 
were found (P > 0.01). No association could be estab- 
lished between the reactivity against either peptide and 
disease progression. 
The geometric mean (G) of the antibody titers for 
each patient was similar for both peptides, ranging 
between 10 and 1000 for C4-6 and between 10 and 
707.13 for C4-7. The patient with code 12 had the high- 
est G values and was asymptomatic (Figure 1). No statis- 
tically significant differences in antibody titers were 
observed between patients with AIDS and those who did 
not have AIDS, or between progressors and nonprogres- 
sors (P > 0.01) (Table 1). 
Avidity Maturation of Anti-V3 Antibodies 
The AI for each sera for peptides C4-6 and C47 was deter- 
mined by the thiocyanate elution method. There was a 
significant difference (P = 0.014) between individuals 
who had been infected for 10 or more years (XC4-6 = 
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Figure 1. Geometric mean of the antibody titers from each patient 
against the studied peptides. The patient with code number 12, exhib- 
ited the highest G values for both peptides. 
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Table 1. General Reactivity of the Sera against Peptides C4-6 and C4-7 
Peptide C4-6 Peptide C4-7 
Sample Percentage Geometric Mean Percentage Geometric Mean 
Category Number of Reactivity (Standard Deviation) of Reactivity (Standard Deviation) 
AIDS (n =3) 23 69.5 82.1 (2.4) 69.5 100.2 (2.1) 
Non-AIDS (n = 7) 22 86.3 23.0 (0.8) 52.1 91.5 (1.4) 
Progressors (n = 7)+ 33 78.7 106.5 (3.6) 88.4 114.2 (3.8) 
Nonprogressors (n = 3)* 12 75.0 113.1 (2.9) 41.6 63.1 (2.6) 
*Asymptomatic patients (n = 3) and those with AIDS-related complex defining diseases (n = 4). +individuals that experienced a change in their clinical classification 
within the period of the study. *Patients who showed nonclinical changes within the study period. 
1.885;XC4-7 = 2.50) and those infected less than 10 years 
(median ~4-6 = 0.59, median C4-7 = 0.57); the difference 
was independent of the clinical stage of the individual. 
The time-course of AI for the 10 individuals is 
depicted in Figure 2. Five of ten patients for ~4-6 and 4 
of 10 for C4-7 showed a maturation in the avidity of their 
sera, according to the criteria previously defined. All three 
nonprogressors showed a significant increment in the AI 
for peptide c4-6, and two of them also increased their 
avidity for C4-7; the AI for the other patient remained 
stable. No signiticant correlation was found between avid- 
ity maturation and disease progression in these patients 
(Table 2). 
DISCUSSION 
Owing to the importance of the V3 loop as the princi- 
pal neutralizing domain of HN, a large number of stud- 
ies have attempted to define the heterogenicity, 
immunogenicity, and antigenic variation of this region. 14,15 
Particular attention has been given to the serologic 
response against V3 in persons infected with HIV-l .6,16 
This report describes a retrospective study for the 
evaluation of the antibody response (titer and avidity 
index) against V3 peptides in 10 Cuban patients infected 
with HIV-l. An indirect ELBA, using 15-merit synthetic 
peptides from the central part of the V3 loop coupled to 
BSA, was employed.” The peptides studied represent 
consensus sequences for HIV-l isolates circulating in 
America and Europe (central tetrapeptide GPGR), or 
Africa (central tetrapeptide GPGQJ. They were chosen 
because the vast majority of cases of HIV infection in 
Cuba originate in these regions.ls 
Despite a wide ELBA reactivity observed, with the 
55.5% of the sera exhibiting a considerable level of cross- 
reactivity for both peptides, no statistically significant dif- 
ferences were found among individuals in different stages 
of the disease. There was no correlation between anti-V3 
reactivity and disease progression. These results are con- 
sistent with other serologic studies that show that sera 
from persons infected with HIV-l can react simultaneously 
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Figure 2. Course of the avidity index (Al) obtained at various time-points within the study period, for peptides C4-6 (A] and C4-7 (f3) in 10 patients 
infected with HIV-l. The Al was higher in the patients infected for 10 or more years (i.e., sera samples 12, 13, 16, 23, 30, and 36). 
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Table 2. Maturation of Antibody Response over Time and 
Disease Progression in 10 Patients Infected with HIV-1 
Avidity Index Peptide C#-6 and C4- 7* 
Increased (5/4) Stable (414) Reduced (l/2) 
Nonprogressor 3/2 O/l o/o 
Progressor 212 4/3 l/2 
*Increased vs. stable or reduced: C4-6, P = 0.16: C4-7, P = 0.29. 
against V3 peptides with rather divergent sequences.‘y,20 
Recently Cheingsong et al found 60% cross-reactivity (3 of 
5 sera) between peptides representing clades B (GPGR) 
and C (GPGQ.’ A high degree of cross-reactivity was also 
found between clades B and D (GPGQ) even in antigen 
limiting ELISA. 
Two different factors could account for such inter- 
clade cross-reactivity in the V3 region. First, an individual 
could have a double infection, with viruses from differ- 
ent clades; second, from the studies of genetic diversity 
in the gp120 and the V3 it is clear that often viruses from 
different clades display considerable similarity within the 
V3 region. l 
A reduced number of conserved residues, most of 
them charged and located at the tip of the loop, appears 
to make a significant contribution to the immunogenic- 
ity of the region and may be responsible for the high 
level of cross-reactivity. It also has been suggested that 
the high mutation rate of HIV could lead to the activation 
and preferential proliferation of B-cell clones secreting 
low-affinity cross-reacting antibodies5 
Conventionally, the investigation of the serologic 
response against different microbial agents has been 
based on the determination of serum antibody titers; how- 
ever, several authors have stressed the importance of esti- 
mating the degree of avidity or affinity of the antibodies 
for the given antigen. 21-25 High-affinity antibodies are more 
effective in many biologic processes than are those of 
lower affinity. These processes include neutralization of 
toxins and viruses, as well as complement furation.26 Pre- 
vious reports have suggested that a gain in the afftity 
(affinity maturation) of neutralizing antibodies correlates 
with a better clinical prognosis for patients with HIV or 
other viruses.21 
Because of these considerations, the authors deter- 
mined the AI of the serum panel against the consensus V3 
peptides. Patients with documented HIV infection of 10 or 
more years’ duration had higher AIs than those of patients 
who had been infected for less than 10 years. These results 
confirm the notion that maturation of antibody affinity 
occurs over time in persons infected with HIV 
It was not possible to demonstrate a correlation 
between antibody titers and avidity index for the sam- 
ples studied. (Data not shown.) This indicates that a 
greater magnitude of antibody response against a given 
epitope does not always reflect an increase in the qual- 
ity of the antibodies that are produced. 
Other studies have focused on the prognostic value 
of HIV serology. The level of antibodies against the inner 
proteins p24 and ~17, the V3 loop, and neutralizing anti- 
bodies has been associated with the course of disease.27-31 
In the present study, although variations in the avidity of 
antibodies against both peptides with time were docu- 
mented, a significant correlation with disease progres- 
sion was not found. The outcome of this retrospective 
study could have been affected by the small number of 
patients evaluated and the relatively short period of obser- 
vation (3 y). Another factor that might have confounded 
the comparison is that only two of the seven patients 
categorized as progressors had severe clinical symptoms. 
In one of these cases the AI remained stable, and in the 
other it was markedly reduced. 
Despite the intense cross-reactivity among V3 pep- 
tides from different clades, some authors have been able 
to discriminate among HIV clades using V3 peptide 
ELISA. The most successful assays have been based on 
the determination of the avidity of the sera for pep- 
tides.*zlO The amino acid sequence of the C2-V3 region 
from the virus isolated from one of the studied patients 
(RKSIHMGPGRALYATED) was available in this study. The 
serum from this individual showed a preferential reac- 
tivity against C4-6 peptides, which shares the central 
tetrapeptide GPGR. 
Further prospective evaluations of a large number of 
patients are needed to clarify whether the quantity or 
quality of anti-V3 antibodies are predictive of disease pro- 
gression at the early stages of infection. 
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